Conditions: Human Immunodeficiency Virus Infections
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 599
Healthy volunteers: no

Brief summary:
The purpose of this study was to compare the safety, tolerability, and antiviral activity of once-daily (QD) and twice-daily (BID) dosing of the lopinavir/ritonavir (LPV/r) tablet formulation in combination with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) in antiretroviral-experienced human immunodeficiency virus type 1 infected subjects with detectable viral load while receiving their current antiretroviral therapy.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) intervention 2: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Intervention descriptions: intervention 1: LPV/r 800/200 mg once-daily (QD) tablet intervention 2: LPV/r 400/100 mg twice-daily (BID) tablet

Protocol document: